VRCAStockVerrica Pharmaceuticals Inc
Verdicts genuinely change. Free email alert the moment VRCA's does — no target price to set, unlike a price alert.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Verrica Pharmaceuticals Inc (VRCA) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 435 compliant Healthcare stocks we track. See compliant Healthcare stocks →
How the status reached this point
Compliant · status tracked since Nov 17, 2026
No change to VRCA’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.
- Nov 21, 2026 Non-compliant → Compliantour daily record began reading this page's own headline on this date; the page's status did not change here
- Nov 20, 2026 Not rated → Non-compliant0 of 3 decided standards pass; figures as of Sep 30, 2026
- Nov 17, 2026 Tracking began Nothing before this date is on record.
Read once a day from the status this page publishes, last on Nov 21, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $57.5M as of 2026-11-19.
Business activity: cleared (no excluded categories detected)
AAOIFI Unverified⚠️ a figure this standard needs was not available, so it could not be scored — the rows below show what was and was not computed 2 of 3 computed, both pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt debt not reported |
not available | 30.00% | Unverified |
| Interest-bearing investments | 25.47% | 30.00% | Pass(4.5pp buffer) |
| Non-permissible income | 2.61% | 5.00% | Pass(2.4pp buffer) |
Usmani Fail 4 of 5 computed, 3 pass, 1 fails
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt debt not reported |
not available | 33.00% | Unverified |
| Interest-bearing investments | 36.77% | 33.00% | Fail(3.8pp over) |
| Non-liquid assets | 35.04% | at least 20.00% | Pass(15.0pp above the floor) |
| Non-permissible income | 2.61% | 5.00% | Pass(2.4pp buffer) |
| Net liquid assets per share | $4.0M | under mkt cap $57.5M | Pass |
MSCI Fail 3 of 4 computed, 1 passes, 2 fail
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt debt not reported |
not available | 33.33% | Unverified |
| Cash + interest-bearing securities | 36.77% | 33.33% | Fail(3.4pp over) |
| Accounts receivable | 64.96% | 33.33% | Fail(31.6pp over) |
| Non-permissible income | 2.61% | 5.00% | Pass(2.4pp buffer) |
FTSE Fail 3 of 4 computed, 1 passes, 2 fail
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt debt not reported |
not available | 33.33% | Unverified |
| Cash + interest-bearing securities | 36.77% | 33.33% | Fail(3.4pp over) |
| Accounts receivable | 64.96% | 50.00% | Fail(15.0pp over) |
| Non-permissible income | 2.61% | 5.00% | Pass(2.4pp buffer) |
Dow Jones Islamic Market Unverified⚠️ a figure this standard needs was not available, so it could not be scored — the rows below show what was and was not computed 3 of 4 computed, all pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt debt not reported |
not available | 33.00% | Unverified |
| Cash + interest-bearing securities | 16.76% | 33.00% | Pass(16.2pp buffer) |
| Accounts receivable | 12.85% | 33.00% | Pass(20.1pp buffer) |
| Non-permissible income | 2.61% | 5.00% | Pass(2.4pp buffer) |
S&P Shariah Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt (bound) | at most 31.23% | 33.00% | Pass |
| Cash + interest-bearing securities | 9.99% | 49.00% | Pass(39.0pp buffer) |
| Accounts receivable | 7.66% | 49.00% | Pass(41.3pp buffer) |
| Non-permissible income | 2.61% | 5.00% | Pass(2.4pp buffer) |
MSCI M-Series Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt (bound) | at most 31.23% | 33.33% | Pass |
| Cash + interest-bearing securities | 9.99% | 33.33% | Pass(23.3pp buffer) |
| Accounts receivable | 17.64% | 49.00% | Pass(31.4pp buffer) |
| Non-permissible income | 2.61% | 5.00% | Pass(2.4pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from VRCA's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $35.6M | 2025-12-31 | Revenues |
| Interest-bearing debtBorrowings — which definition was stored is not recorded | not measured | — | — |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $14.7M | 2026-09-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
| Total assetsBalance sheet total | $39.9M | 2026-09-30 | Assets |
| Market capDenominator for AAOIFI | $57.5M | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $116.0M | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $65.1M | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $929.0K | 2025-12-31 | InvestmentIncomeInterest |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-13, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-03-11, period ended 2025-12-31. Screened 2026-11-19.
-
Total assets$39.9M
Assets· period ended 2026-09-30 · 10-Q filed 2026-11-13 -
Cash and interest-bearing securities$14.7M
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents· period ended 2026-09-30 · 10-Q filed 2026-11-13 -
Receivables$11.2M
AccountsReceivableNetCurrent· period ended 2026-09-30 · 10-Q filed 2026-11-13 -
Revenue$35.6M
Revenues· period ended 2025-12-31 · 10-K filed 2026-03-11 -
Interest income (non-permissible)$929.0K
InvestmentIncomeInterest· period ended 2025-12-31 · 10-K filed 2026-03-11 -
Market cap$57.5MMarket quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-19 · not a filing figure, so no link
5 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.
What changed, and when
Verdict history for VRCA. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-11-19 Unverified → Fail filing re-screen
Tracked since 2026-09-07.
Shariah-compliant alternatives
Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| VRTXVertex Pharmaceuticals, Inc. | $121.1B | — |
| REGNRegeneron Pharmaceuticals, Inc. | $85.3B | — |
| ARGXArgen X SE - ADR | $64.3B | — |
| ONCBeOne Medicines Ltd. American Depositary Shares | $40.4B | — |
| ALNYAlnylam Pharmaceuticals Inc | $31.6B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Griffin | Citadel Advisors | $0M | 0.0% | 2026-09-30 |
| Peter Brown | Renaissance Technologies | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 34.00 | NEUTRAL |
| Stochastic %K (14) | 0.68 | BUY |
| CCI (20) | -185.64 | BUY |
| Williams %R (14) | -99.32 | BUY |
| MACD (12,26,9) | -0.04 | SELL |
| ROC (10) | -14.11 | SELL |
| Momentum (10) | -0.45 | SELL |
| EMA (10) | 3.15 | SELL |
| SMA (10) | 3.31 | SELL |
| EMA (20) | 3.34 | SELL |
| SMA (20) | 3.32 | SELL |
| EMA (30) | 3.50 | SELL |
| SMA (30) | 3.44 | SELL |
| EMA (50) | 3.81 | SELL |
| SMA (50) | 3.85 | SELL |
| EMA (100) | 4.44 | SELL |
| SMA (100) | 4.61 | SELL |
| EMA (200) | 5.28 | SELL |
| SMA (200) | 5.30 | SELL |
About Verrica Pharmaceuticals Inc
Healthcare · Biotechnology
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-08-28
Stop 4.96 Now 2.74 Target 5.29
🟠 NOT YET
The main driver: lagging the market by 16.8%. More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.
Scores: 1 bullish / 2 bearish
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
Still fetching the market-structure read — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-17 · Asset managers net 895049 (-19081)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.